Rhythm Pharmaceuticals, Inc. (RYTM): Price and Financial Metrics
RYTM Price/Volume Stats
| Current price | $47.55 | 52-week high | $50.28 |
| Prev. close | $47.79 | 52-week low | $15.50 |
| Day low | $46.40 | Volume | 489,600 |
| Day high | $48.59 | Avg. volume | 732,896 |
| 50-day MA | $42.49 | Dividend yield | N/A |
| 200-day MA | $27.05 | Market Cap | 2.81B |
RYTM Stock Price Chart Interactive Chart >
RYTM POWR Grades
- RYTM scores best on the Growth dimension, with a Growth rank ahead of 37.34% of US stocks.
- The strongest trend for RYTM is in Stability, which has been heading up over the past 26 weeks.
- RYTM's current lowest rank is in the Quality metric (where it is better than 4.21% of US stocks).
RYTM Stock Summary
- For RYTM, its debt to operating expenses ratio is greater than that reported by just 4.27% of US equities we're observing.
- With a price/sales ratio of 41.84, RHYTHM PHARMACEUTICALS INC has a higher such ratio than 96.31% of stocks in our set.
- Revenue growth over the past 12 months for RHYTHM PHARMACEUTICALS INC comes in at 271.94%, a number that bests 98.14% of the US stocks we're tracking.
- Stocks that are quantitatively similar to RYTM, based on their financial statements, market capitalization, and price volatility, are TFFP, TDUP, IMNM, ASTC, and CYN.
- RYTM's SEC filings can be seen here. And to visit RHYTHM PHARMACEUTICALS INC's official web site, go to www.rhythmtx.com.
RYTM Valuation Summary
- In comparison to the median Healthcare stock, RYTM's price/sales ratio is 1890.91% higher, now standing at 43.8.
- Over the past 76 months, RYTM's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for RYTM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RYTM | 2023-12-29 | 43.8 | 13.8 | -14.6 | -15.4 |
| RYTM | 2023-12-28 | 44.9 | 14.1 | -15.0 | -15.7 |
| RYTM | 2023-12-27 | 47.3 | 14.9 | -15.8 | -16.6 |
| RYTM | 2023-12-26 | 45.8 | 14.4 | -15.3 | -16.1 |
| RYTM | 2023-12-22 | 44.2 | 13.9 | -14.8 | -15.5 |
| RYTM | 2023-12-21 | 43.0 | 13.5 | -14.4 | -15.1 |
RYTM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RYTM has a Quality Grade of F, ranking ahead of 2.46% of graded US stocks.
- RYTM's asset turnover comes in at 0.004 -- ranking 418th of 681 Pharmaceutical Products stocks.
- EVOK, ATRA, and EVFM are the stocks whose asset turnover ratios are most correlated with RYTM.
The table below shows RYTM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.004 | 0.728 | -0.232 |
| 2021-06-30 | 0.001 | 0.544 | -0.211 |
| 2021-03-31 | 0.000 | 0.886 | -0.196 |
| 2020-12-31 | 0.000 | NA | -0.922 |
| 2020-09-30 | 0.000 | NA | -0.718 |
| 2020-06-30 | 0.000 | NA | -0.784 |
RYTM Price Target
For more insight on analysts targets of RYTM, see our RYTM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $36.67 | Average Broker Recommendation | 1.71 (Moderate Buy) |
Rhythm Pharmaceuticals, Inc. (RYTM) Company Bio
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was founded in 2008 and is based in Boston, Massachusetts.
Latest RYTM News From Around the Web
Below are the latest news stories about RHYTHM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RYTM as an investment opportunity.
Rhythm Pharmaceuticals Announces New Employment Inducement GrantsBOSTON, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on December 7, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 10,500 shares of its common stock to o |
Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023-- More than 50 poster presentations highlighting new scientific developments to advance the care of people living with rare MC4R pathway diseases -- -- Approximately 150 healthcare professionals from 20 countries expected to attend -- BOSTON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocor |
Insider Sell Alert: CFO Hunter Smith Sells 27,026 Shares of Rhythm Pharmaceuticals Inc (RYTM)In a recent transaction on December 6, 2023, Hunter Smith, the Chief Financial Officer (CFO) of Rhythm Pharmaceuticals Inc, sold a significant number of shares in the company. |
Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event-- Phase 3 trial evaluating setmelanotide in pediatric patients ages 2-<6yo (N=12) over 52 weeks achieved primary endpoint -- -- Setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in patients ages 2-<6yo with obesity due to POMC/LEPR deficiency or BBS -- -- RM-718 showed potential to reduce body weight and hyperphagia with no off-target cardiovascular effects and no hyperpigmentation observed in pre-clinical studies; first in-human studies anticipate |
Insider Sell Alert: Joseph Shulman of Rhythm Pharmaceuticals Inc Cashes Out SharesIn the realm of biopharmaceuticals, insider transactions are often scrutinized for insights into the company's health and future prospects. |
RYTM Price Returns
| 1-mo | 11.83% |
| 3-mo | 67.08% |
| 6-mo | 78.56% |
| 1-year | 70.25% |
| 3-year | 39.04% |
| 5-year | 67.72% |
| YTD | 3.44% |
| 2023 | 57.86% |
| 2022 | 191.78% |
| 2021 | -66.43% |
| 2020 | 29.49% |
| 2019 | -14.58% |
Loading social stream, please wait...